Layoffs
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
Key Facts
Signal Type
Layoffs
Industry
Biotech
Companies
Molecular Partners, Novartis, Amgen, Zai Lab
Date
Molecular Partners, a Zurich-based biotech, announced plans to lay off up to 44% of its workforce, affecting up to 55 positions. The restructuring is part of a strategic pivot to focus the company's declining cash reserves on its radiotherapeutic pipeline. The company expects to implement the changes by the second quarter of 2027, with the full cost reduction effects felt in the second half of that year.
The layoffs will impact up to 55 employees across the organization. Molecular Partners is consulting with employees as required under Swiss law. The company is prioritizing its phase 1/2a study of MP0712, a DLL3-targeting radiopharmaceutical for small cell lung cancer, and advancing its broader "Radio-DARPin" pipeline. Other programs, including the multispecific T-cell engager MP0533 and the bispecific MP0317, are being deprioritized as the company shifts focus exclusively to radiopharmaceuticals, with plans to explore immune cell engagers through strategic partnerships and spinout opportunities.
Key milestones include initial safety data from the MP0712 phase 1/2a study expected in December 2026, with efficacy results following in 2027. The second radiopharmaceutical program, MP0726, is advancing to first-in-human imaging in the second half of 2026, and MP0730 could enter first-in-human studies in mid-2027. Additionally
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
